The
central nervous system drugs market includes medications that are used in the
treatment of diseases affecting the brain or spinal cord. The central nervous
system (CNS) integrates sensory information and instructs the body to respond
accordingly. The spinal cord is a channel for signals between the brain and the
rest of the body. Central nervous system (CNS) disorder is a condition in which
the brain and spinal cord’s ability to function is affected, hence affecting
the body. The market for CNS disorder drugs comprises of drugs that work in
different ways depending on the type of disease by suppressing or boosting the
brain activities.
The
substantial growth of the market from $72 billion in 2017 to around $90 billion
by 2021 is due to the steps taken by the US FDA (Food and Drug Administration)
and EMA (European Medicines Agency) to offer allotment of special regulatory
designations for Central Nervous System disorders which will help in the faster
entry of drugs into the market for treatment of serious nervous system related
conditions. The geriatric population and rise in diseases such as Parkinson’s,
Alzheimer’s and other mental disorders is also likely to continue to drive the
market for central nervous system drugs.
In the
report, the global central nervous system drugs market is divided into five
segments. Other CNS drugs occupy the major share, accounting for more than
two-fifth of the market. Anaesthetics is the second largest segment, occupying
one-fifth of the market share and the remaining two-fifth of the market share
is occupied by the other three segments namely, analgesics, anti-parkinson
drugs and anti-epileptics.
Sample Report:
The USA was the largest country in the central nervous system drugs
market in 2017, accounting for more than one-fourth of the market share. This
can be attributed to high drug prices and increased healthcare spending in the
USA compared to other countries. Germany and China followed the USA as the next
largest countries in the market.
The
central nervous system drugs market is fragmented with a number of large and
small organizations. The top five competitors in the market made up around two-fifth
of the total market in 2017. Biogen Inc. was the largest competitor of the
market, followed by F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer
Inc. and Novartis AG. Biogen Inc. was founded in 1978 and is headquartered in
Massachusetts, USA. It is involved in discovering, developing, and selling
medical products used to treat neurological disorders such as multiple
sclerosis, and inflammatory diseases such as rheumatoid arthritis. Biogen Idec
has offices in Australia, the Brazil, Japan, India, and China.
About
The Business Research Company.
The
Business Research Company is a Business Intelligence Company which excels in
company, market and consumer research. It has
offices in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact
Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
No comments:
Post a Comment